Disparate animal species and strains, with a variety of metabolic pathways and drug metabolites
Different models for inducing illness or injury with varying similarity to the human condition
Variations in drug dosing schedules and regimen that are of uncertain relevance to the human condition
Variability in the way animals are selected for study methods of randomization, choice of comparison therapy (none, placebo, vehicle), and reporting of loss to follow up
Small experimental groups with inadequate power, simplistic statistical analysis that does not account for potential confounding, and failure to follow intention to treat principles
Nuances in laboratory technique that may influence results may be neither recognized nor reported—eg methods for blinding investigators
Selection of a variety of outcome measures, which may be disease surrogates or precursors and which are of uncertain relevance to the human clinical condition
Length of follow up before determination of disease outcome varies and may not correspond to disease latency in humans